A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

Research shows routine follow-up misses most relapses in lymphoma patients in remission, highlighting the need for improved ...

"Imugene doses first Australian subject in trial of B-cell lymphoma drug candidate" was originally created and published by ...

XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Diffuse Large B-Cell Lymphoma.

Dr John Leonard shares key updates on DLBCL at ASH 2024, including long-term POLARIX trial data, ctDNA insights, and real-world results for polatuzumab, liso-cel, and bispecifics after CAR-T failure.

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within ...

BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics (Foresight), a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today provided its strategic ...

Navi Mumbai: In a medical breakthrough at Kokilaben Dhirubhai Ambani Hospital, Navi Mumbai, a 39-year-old Rijesh Nair, a ...

Diffuse large B-cell lymphoma, which accounts for nearly half of all non-Hodgkin lymphoma (NHL) cases, is particularly aggressive and presents significant challenges for both patients and ...

As we start the New Year, it’s time to schedule your annual wellness visit. This important appointment is to talk about any ...

Panelists discuss how a diagnosis of diffuse large B-cell lymphoma or follicular lymphoma affects patients physically and emotionally and how these challenges shape their treatment journey and overall ...